Nathan Fountain, a neurologist at the University of Virginia School of Medicine who was chair of the November independent advisory panel, hopes that there is room for compromise. “It would have been wrong to approve the drug as a first-line treatment for MS”, says Fountain. “But for more aggressive disease, or for second line therapy, an approval would have been reasonable.”